Study to Assess the Effect of Rifampicin on Blood Levels and Safety of AZD9291, in Patients With EGFRm+ NSCLC

Clinical trial NCT02197247 · COMPLETED

Trial details

NCT number: NCT02197247
Sponsor: AstraZeneca
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Non Small Cell Lung Cancer

Start date: 2014-12-04
Primary completion: 2015-07-09
Enrollment: 41

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.